Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics
Current Opinion in Nephrology and Hypertension, 06/01/2012
Petruzziello–Pellegrini T et al. – A better understanding of Shiga toxin–producing Escherichia coli–mediated hemolytic uremic syndrome underlies improved therapeutic approaches. New studies of the mechanistic basis of the disease, together with patient–based studies, have led to key findings with important clinical implications.